Revolution Medicines' pancreatic cancer drug proving hard to get
statnews.com • • health
Key Points:
- Amy Johnston, diagnosed with pancreatic cancer last year, is currently in a clinical trial and hopes to delay disease progression, but is preparing to seek access to a promising experimental drug if the trial is unsuccessful.
- The drug, daraxonrasib by Revolution Medicines, nearly doubled overall survival time in pancreatic cancer patients during a clinical trial and is now available through an expanded access program for critically ill patients.
- Despite optimism about daraxonrasib’s potential as a second-line therapy, high demand and limited supply have caused anxiety among patients about availability and prioritization.
- Johnston expressed concerns about the small company’s ability to produce enough of the drug and the fairness in determining who receives it first, especially for those needing it as a last resort.